Compare AbCellera Biologics Inc (ABCL) vs General Dynamics Corporation (GD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs General Dynamics Corporation — how do they compare? AbCellera Biologics Inc trades at $7.26 (market cap $2.35B), while General Dynamics Corporation trades at $372.8 (market cap $101.31B). The key difference: General Dynamics Corporation is far larger — about 43.1× AbCellera Biologics Inc's market cap, and General Dynamics Corporation pays a 1.7% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | GD | |
|---|---|---|
Market Cap | $2.35B | $101.31B |
Sector | Health | Industrials |
52-Week High | $8.12 | $376.88 |
52-Week Low | $2.78 | $296.65 |
Enterprise Value | $1.99B | $107.49B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
General Dynamics (GD) trades at $374.64, up 0.29% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving average signals, while fundamentals are solid with revenue growth to $52.55 billion in 2025 and net income of $4.21 billion. Recent earnings beats and a massive $130.8 billion backlog support positive momentum, with analyst consensus leaning bullish.
Outlook remains favorable given defense budget tailwinds and execution strength, but valuation multiples like P/E of 23.72 suggest limited upside from current levels. Risks include contract execution delays and macroeconomic pressures. The stock offers steady growth and income via dividends, but investors should weigh rich valuations against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →
